BeiGene, Ltd. IPO Research Information

BeiGene, Ltd. IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on BeiGene, Ltd., and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
BeiGene, Ltd.	BGNE - NASDAQ	$15.00-$17.00	$24.00	$28.97	6.6 million	2/3/2016
Underwriter(s): Goldman Sachs & Co., Morgan Stanley, Cowen & Co.
Co-Manager(s): Baird
Industry: Health Care
Filing(s): Filed 2015-10-16 Terms Added 2016-01-19

BeiGene, Ltd. Quote & Chart - Click for current quote - BGNE

About BeiGene, Ltd. (adapted from BeiGene, Ltd. prospectus):
They are a globally focused biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "BGNE" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.